Our vacancies
For a career in Biotech, Medtech or Hightech
Executive Assistant
Founded in 1959, the French group PREVOR is a toxicology and chemical risk control laboratory whose aim is to maximise the safety of people faced with burns and chemical risks.
Thanks to its research and solutions aimed at reducing the frequency and severity of chemical accidents, the PREVOR group has become a daily partner of manufacturers, emergency services and hospitals.
Operating in more than 45 countries, the PREVOR group helps its customers to ensure that a chemical accident remains an incident, through prevention training and the development of first-aid equipment.
The group's three divisions (First Aid, Environment and Health) offer modern, reliable solutions to optimise the safety of people and the environment.
Due to the growth of its activities, our client PREVOR is looking for an "Executive Assistant" based in Liège (Belgium):
Senior RA Specialist EU
Our client, Nyxoah (https://www.nyxoah.com ), is a health-technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution is the Genio® system, a CE-mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
In September 2021, the US Food and Drug Administration (FDA) has granted the Genio® bilaterial hypoglossal nerve stimulation system Breakthrough Devise Designation for the treatment of adult patients with moderate to severe OSA and Complete Concentric Collapse (CCC) of the soft palate.
The Breakthrough Designation is supported by data from the Company’s BETTER SLEEP trial, aimed at addressing the long-term safety and performance of the Genio® system in adult OSA patients with and without CCC.
Médecin investigateur
ATC Pharma est un Centre de Recherche Clinique spécialisé dans la réalisation d’essais cliniques "Early Phase".
NPI Process Engineer -Medtech
Our client, Nyxoah (https://www.nyxoah.com ), is a health-technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution is the Genio® system, a CE-mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
In September 2021, the US Food and Drug Administration (FDA) has granted the Genio® bilaterial hypoglossal nerve stimulation system Breakthrough Devise Designation for the treatment of adult patients with moderate to severe OSA and Complete Concentric Collapse (CCC) of the soft palate.
The Breakthrough Designation is supported by data from the Company’s BETTER SLEEP trial, aimed at addressing the long-term safety and performance of the Genio® system in adult OSA patients with and without CCC.